ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Potential Interactions Between Cocaine and Tolcapone - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00033059
Recruitment Status : Unknown
Verified August 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : April 8, 2002
Last Update Posted : January 11, 2017
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to assess the potential interactions between intravenous (IV) cocaine and tolcapone.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Drug: Tolcapone Phase 1

Detailed Description:
Double-blind, inpatient study by screening responses to cocaine infusions of 20 and 40 mg i.v. subjects into 1 of 2 treatment groups to assess potential interactions between i.v. cocaine infusion and treatment with tolcapone.

Study Type : Interventional  (Clinical Trial)
Enrollment : 16 participants
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Assessment of Potential Interactions Between Intravenous Cocaine and Tolcapone
Study Start Date : July 2001
Study Completion Date : March 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions
Drug Information available for: Tolcapone
U.S. FDA Resources




Primary Outcome Measures :
  1. Safety


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Volunteers dependent on cocaine and are non-treatment seeking; between 18-45 yrs of age; DSM-4 criteria for cocaine abuse or dependence

Exclusion Criteria:

Additional criteria available during screening at the site


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00033059


Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Thomas Newton, M.D. National Institute on Drug Abuse (NIDA)

ClinicalTrials.gov Identifier: NCT00033059     History of Changes
Obsolete Identifiers: NCT00024765
Other Study ID Numbers: NIDA-CTO-0003-1
First Posted: April 8, 2002    Key Record Dates
Last Update Posted: January 11, 2017
Last Verified: August 2003

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Tolcapone
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Catechol O-Methyltransferase Inhibitors
Enzyme Inhibitors